ArticleFrontiers in immunology2022

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.

Shubin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.